Patents by Inventor Lere Bao

Lere Bao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170184600
    Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.
    Type: Application
    Filed: August 9, 2016
    Publication date: June 29, 2017
    Inventors: BRUCE R. ZETTER, Lere Bao, Jacqueline Banyard
  • Publication number: 20120115134
    Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.
    Type: Application
    Filed: July 12, 2011
    Publication date: May 10, 2012
    Applicant: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao, Jacqueline Banyard
  • Patent number: 7993863
    Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: August 9, 2011
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao, Jacqueline Banyard
  • Patent number: 7592145
    Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin1 and the amplification of Pin1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: September 22, 2009
    Assignee: Pintex Pharmaceuticals, Inc.
    Inventors: Lere Bao, Da Gong Wang
  • Publication number: 20060216764
    Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin1 and the amplification of Pin1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.
    Type: Application
    Filed: June 5, 2006
    Publication date: September 28, 2006
    Inventors: Lere Bao, Da Wang
  • Publication number: 20060105343
    Abstract: We have discovered a protein in humans, herein referred to as thymosin R16 (SEQ ID NO: 1), that is expressed in human prostate cancer tumors but not in specimens of benign prostate hyperplasma (BPH) tissues. In contrast, prostate specific antigen (PSA), the gold standard of prostate cancer diagnosis, is highly expressed in BPH tissues. Increased expression of thymosin (316 has a high correlation to disease state in a number of cancers including prostate cancer and cancers of epithelial origin. Accordingly, method of diagnosing and prognosing cancer in a patient by measuring the level of thymosin (316 in a biological test sample obtained from the patient are provided.
    Type: Application
    Filed: January 7, 2004
    Publication date: May 18, 2006
    Applicant: Children's Medical Center Corporation
    Inventors: Bruce Zetter, Lloyd Hutchinson, Lere Bao
  • Publication number: 20060078882
    Abstract: We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested.
    Type: Application
    Filed: March 18, 2003
    Publication date: April 13, 2006
    Inventors: Bruce Zetter, Lere Bao, Jacqueline Banyard
  • Publication number: 20040101910
    Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr; 15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr; 15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
    Type: Application
    Filed: December 3, 2003
    Publication date: May 27, 2004
    Applicant: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao
  • Publication number: 20030073096
    Abstract: This invention provides methods for diagnosing prostate cancer, methods for measuring the aggressiveness of prostate cancer, and methods for identifying prostate cancer likely to metastasize. The diagnostic and prognostic assays of this invention include methods involving the antibody-based detection of Pin 1 and the amplification of Pin 1 RNA. The diagnostic and prognostic assays of this invention may be used in combination with other methods of prostate cancer diagnosis including the PSA test, digital rectal exam, and Gleason prostate tumor grading system.
    Type: Application
    Filed: February 8, 2002
    Publication date: April 17, 2003
    Applicant: Pintex Pharmaceuticals, Inc.
    Inventors: Lere Bao, Da Gong Wang
  • Publication number: 20030068626
    Abstract: Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels.
    Type: Application
    Filed: February 8, 2002
    Publication date: April 10, 2003
    Applicant: Pintex Pharmaceuticals, Inc.
    Inventors: Da Gong Wang, Lere Bao
  • Publication number: 20020183496
    Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr;15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr;15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
    Type: Application
    Filed: June 5, 2001
    Publication date: December 5, 2002
    Applicant: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 6489463
    Abstract: The present invention provides a thymosin &bgr;15 promoter. The promoter comprises the nucleotide sequence of SEQ ID NO:1 or a fragment thereof capable of expressing an operably linked DNA. A DNA sequence having nucleotides −400 to +1 of FIG. 1 is a preferred fragment. The invention also provides novel assays for identifying compounds useful in the treatment of malignancies involving modulation of thymosin &bgr;15 expression, e.g., breast, pancreas and prostate cancer. The invention further provides a method of human gene therapy for treating malignancies involving up-regulation of thymosin &bgr;15 expression.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: December 3, 2002
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 6300479
    Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin &bgr; family. This novel protein, herein referred to as thymosin &bgr;15, has the ability to bind and sequester G-actin, like other members of the thymosin &bgr; family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin &bgr;15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: October 9, 2001
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 6150117
    Abstract: The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin .beta.15 gene (SEQ ID NO: 1) and having the deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that enhanced transcripts (mRNA) and expression of the thymosin .beta.15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.
    Type: Grant
    Filed: August 18, 1998
    Date of Patent: November 21, 2000
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 6017717
    Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: January 25, 2000
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 5858681
    Abstract: The present inventors have discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members also directly regulates cell motility in prostatic carcinoma cells. A cDNA of the human thymosin .beta.15 gene (SEQ ID NO: 1) and having the deduced the amino acid sequence (SEQ ID NO: 2) was isolated. The present inventors have shown that enhanced transcripts (mRNA) and expression of the thymosin .beta.15 gene in non-testicular cells has a high correlation to disease state in a number of cancers, such as prostate, lung, melanoma and breast cancer, particularly metastatic cancers. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be used in not only a diagnostic manner, but a prognostic manner for particular cancers.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: January 12, 1999
    Assignee: Children's Medical Center
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 5831033
    Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: November 3, 1998
    Assignee: Children's Medical Center of Boston
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 5721337
    Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: February 24, 1998
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 5663071
    Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is directed to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: September 2, 1997
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao